These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 10847146)

  • 1. [Arterial hypertension and obesity--a dangerous combination].
    Zakharieva S
    Vutr Boles; 1999; 31(1):28-32. PubMed ID: 10847146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Leptin to adiponectin ratio, as an index of insulin resistance and atherosclerosis development].
    Kieć-Klimczak M; Malczewska-Malec M; Huszno B
    Przegl Lek; 2008; 65(12):844-9. PubMed ID: 19441676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central and peripheral contributions to obesity-associated hypertension: impact of early overnourishment.
    Morris MJ; Velkoska E; Cole TJ
    Exp Physiol; 2005 Sep; 90(5):697-702. PubMed ID: 16105938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Obesity and hypertension].
    Verdecchia P; Trimarco B
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):54S-59S. PubMed ID: 18773751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Insulin resistance: an etiological factor in essential arterial hypertension and coronary cardiopathy].
    Vázquez Chávez C; Brito Zurita OR; Argüero Sánchez R; Lozano de los Santos H
    Gac Med Mex; 1993; 129(5):339-45. PubMed ID: 7926420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension.
    Baltatzi M; Hatzitolios A; Tziomalos K; Iliadis F; Zamboulis Ch
    Int J Clin Pract; 2008 Sep; 62(9):1432-40. PubMed ID: 18793378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The treatment of obesity-related hypertension].
    Skoczylas A
    Wiad Lek; 2006; 59(5-6):403-6. PubMed ID: 17017491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Obesity and cardiovascular diseases-theoretical background and therapeutic consequences].
    Völler H; Schmailzl KJ; Bjarnason-Wehrens B
    Z Kardiol; 2004 Jul; 93(7):503-13. PubMed ID: 15243761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin signaling and obesity: cardiovascular consequences.
    Yang R; Barouch LA
    Circ Res; 2007 Sep; 101(6):545-59. PubMed ID: 17872473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and hypertension.
    Hsueh WA; Buchanan TA
    Endocrinol Metab Clin North Am; 1994 Jun; 23(2):405-27. PubMed ID: 8070430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of aldosterone with obesity-related hypertension and the metabolic syndrome.
    Vogt B; Bochud M; Burnier M
    Semin Nephrol; 2007 Sep; 27(5):529-37. PubMed ID: 17868790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension in obesity.
    Redon J
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):344-53. PubMed ID: 11887431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity-hypertension: an ongoing pandemic.
    Francischetti EA; Genelhu VA
    Int J Clin Pract; 2007 Feb; 61(2):269-80. PubMed ID: 17263714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy.
    Tankó LB; Christiansen C
    Climacteric; 2006 Jun; 9(3):169-80. PubMed ID: 16766431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hypertension in the patients with obesity].
    Hano T; Nishio I
    Nihon Rinsho; 2001 May; 59(5):973-7. PubMed ID: 11392001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in resting metabolic rate and ratio of plasma leptin to urinary nitric oxide: influence on obesity-related hypertension.
    Golan E; Tal B; Dror Y; Korzets Z; Vered Y; Weiss E; Bernheim J
    Isr Med Assoc J; 2002 Jun; 4(6):426-30. PubMed ID: 12073415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin and the clinical cardiovascular risk.
    Singh M; Bedi US; Singh PP; Arora R; Khosla S
    Int J Cardiol; 2010 Apr; 140(3):266-71. PubMed ID: 19944469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors.
    Hernández-Mijares A; Jarabo-Bueno MM; López-Ruiz A; Solá-Izquierdo E; Morillas-Ariño C; Martínez-Triguero ML
    Int J Obes (Lond); 2007 Jun; 31(6):927-32. PubMed ID: 17264851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.